信达生物(01801.HK)续涨7%再创纪录高 向印尼药企授出「达攸同」独家许可
日前获大和调高目标价57%至110元的信达生物(01801.HK)向印尼药企授出「达攸同」独家许可。该股今天升破上周四所创纪录高位98.85元,最高见105.2元纪录高,现造103.7元,续升7%,成交654万股,涉资6.7亿元。
信达生物昨天收市後公布,与印尼生物科技公司PT Etana Biotechnologies Indonesia (Etana)签订合作协议,授予Etana贝伐珠单抗注射液「达攸同」在印尼的独家许可,信达将获得开发及销售里程碑付款,与双位数比例净销售额提成。
信达本月中曾公布拟以每股90.9元(较市价折让不足半成)配售5,200万股,净筹46.71亿元用作加快投资及开发公司全球领先创新产品的多项临床试验计划等。
Follow us
Find us on
Facebook,
Twitter ,
Instagram, and
YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the
uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!

Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements. Any calculations or images in the article are for illustrative purposes only.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance. Please carefully consider your personal risk tolerance, and consult independent professional advice if necessary.